IP Library › Granted Patent US 12,297,469
Granted Patent B2
US 12,297,469 · App. 17/748,163 · Granted May 13, 2025

Methods and compositions for inhibiting ADAM10 biological activities

Inventors: Marcia L. Moss (Apex, NC); Robert Rasmussen (Lansing, NY); Chris Prince (Ithaca, NY)
Assignee: VERRA THERAPEUTICS, INC.
C12N9/6489A61K38/4886A61K47/60A61P37/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,297,469
App. No.
17/748,163
Granted
May 13, 2025
Kind
B2
Abstract

Provided are modified isolated ADAM10 modulating peptides and methods of using the same to modulate ADAM10 biological activities, inhibit ADAM10 biological activities associated with diseases, disorders, or conditions in subjects, including but not limited to decreasing inflammation and inhibiting undesirable cell proliferation. In some embodiments, the modified isolated ADAM10 modulating peptides are based on SEQ ID NO: 3 or SEQ ID NO: 4, and in some embodiments include modifications at or near the N-terminal and/or the C-terminal ends of the disclosed peptides as well as substitutions, insertions, and deletions at one or more amino acid positions of the ADAM10 prodomain peptides disclosed herein.

Claims (19)

1. A peptide comprising an amino acid sequence at least 90% identical to SEQ ID NO: 62, wherein amino acid position number 29 is not arginine, amino acid position number 55 is not arginine, amino acid position number 151 is not cysteine, and amino acid position number 177 is not glutamine.

2. The peptide of claim 1 , wherein the amino acid at position number 29 is alanine.

3. The peptide of claim 1 , wherein the amino acid at position number 29 is glycine.

4. The peptide of claim 3 , wherein the amino acid at position number 55 is glycine.

5. The peptide of claim 4 , wherein the amino acid at position number 151 is serine.

6. The peptide of claim 5 , wherein the amino acid at position number 177 is alanine.

7. The peptide of claim 6 , which comprises an amino acid sequence at least 95% identical to SEQ ID NO: 62.

8. The peptide of claim 4 , wherein the amino acid at position number 177 is alanine.

9. The peptide of claim 3 , wherein the amino acid at position number 151 is serine.

10. The peptide of claim 3 , wherein the amino acid at position number 177 is alanine.

11. The peptide of claim 1 , wherein the amino acid at position number 55 is alanine.

12. The peptide of claim 1 , wherein the amino acid at position number 55 is glycine.

13. The peptide of claim 12 , wherein the amino acid at position number 151 is serine.

14. The peptide of claim 12 , wherein the amino acid at position number 177 is alanine.

15. The peptide of claim 1 , wherein the amino acid at position number 151 is serine.

16. The peptide of claim 1 , wherein the amino acid at position number 177 is alanine.

17. The peptide of claim 1 , which comprises the amino acid sequence of SEQ ID NO: 3 in which position 26 is arginine, position 27 is alanine, position 28 is lysine, position 29 is glycine, position 34 is glutamic acid, position 35 is aspartic acid, position 36 is glutamine, position 52 is arginine, position 53 is methionine, position 54 is lysine, position 55 is alanine, position 62 is aspartic acid, position 63 is glutamic acid, position 88 is glutamic acid, position 89 is glutamic acid, position 136 is glutamic acid, position 137 is aspartic acid, position 138 is aspartic acid, position 151 is serine, position 169 is glutamic acid, position 170 is glutamic acid, position 176 is glutamine, position 177 is alanine, and position 178 is glutamic acid.

18. A pharmaceutical composition comprising the peptide of claim 1 and a pharmaceutically acceptable carrier or excipient.

19. A method of inhibiting A Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) activity comprising administering the peptide of claim 1 to a human subject in need thereof.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Feb 25, 2025
From: VERRA THERAPEUTICS, LLC; VERRA THERAPEUTICS, INC.
To: VERRA THERAPEUTICS, INC.
Reel/Frame 070322/0727 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2022
From: MOSS, MARCIA L.; RASMUSSEN, ROBERT; PRINCE, CHRIS
To: VERRA THERAPEUTICS LLC
Reel/Frame 059974/0832 →
Continuity (4)
Continuation 16149764 · Oct 2, 2018
Provisional Application 62589842 · Nov 22, 2017
Provisional Application 62566580 · Oct 2, 2017
Related Publication 20230203468A1 · Jun 29, 2023
References Cited (49)
US 8034783B2 · Moss et al. · 2011 [cited by applicant]
US 20080096820A1 · Moss et al. · 2008 [cited by applicant]
US 20090285640A1 · Hilfiker et al. · 2009 [cited by applicant]
US 20090285840A1 · Blobel et al. · 2009 [cited by applicant]
US 20090297507A1 · Lai et al. · 2009 [cited by applicant]
US 20100111951A1 · Mather et al. · 2010 [cited by applicant]
US 20120130044A1 · Bachovchin et al. · 2012 [cited by applicant]
US 20130059788A1 · Moss et al. · 2013 [cited by applicant]
WO WO2004024089A2 · 2004 [cited by applicant]
WO WO2012064865A1 · 2012 [cited by applicant]
WO WO2012088105A2 · 2012 [cited by applicant]
WO WO2015117199A1 · 2015 [cited by applicant]
Timothy M. Smith Jr, Targeting ADAM10 in Cancer and Autoimmunity, Front. Immunol. 11:499, 2020. [cited by examiner]
Mechanisms of Carcinogenesis, Secition 3, 2008, International Agency for Research on Cancer. [cited by examiner]
Bertenshaw et al., Marked Differences between Metalloproteases Meprin A and B in Substrate and Peptide Bond Specificity, J. B. Chem., 276(16):13248-13255 (2001). [cited by applicant]
European Application No. 18865159.0, Supplementary European search report and Search Opinion, mailed Aug. 4, 2021. [cited by applicant]
European Application No. 18865159.0, Supplementary European search report and Search Opinion, mailed Dec. 22, 2021. [cited by applicant]
Hosaka et al., Arg-X-Lys/Arg-Arg Motif as a Signal for Precursor Cleavage Catalyzed by Furin within the Constitutive Secretory Pathway, J. Biol. Chem., 266(19):12127-30 (1991). [cited by applicant]
International Application No. PCT /US2018/053938, International Preliminary Report on Patentability, mailed Apr. 16, 2020. [cited by applicant]
Banerjee et al. (2011) American Journal of Physiology-Gastrointestinal and Liver Physiology 300:G273-282. [cited by applicant]
Bech-Serra et al. (2006) Proteomic identification of desmoglein 2 and activated leukocyte cell adhesion molecule as substrates of ADAM17 and ADAM10 by difference gel electrophoresis. Molecular and Cellular Biology 26(13… [cited by applicant]
Bergin et al. (2008) Journal of Biological Chemistry 283:31736-31744. [cited by applicant]
Dreymueller et al. (2015) ADAM-family metalloproteinases in lung inflammation: potential therapeutic targets. American Journal of Physiology Lung Cellular and Molecular Physiology 308(4):L325-43. [cited by applicant]
Dreymueller et al., Consideration on inhibition approaches for proinflammatory functions of ADAM proteases, [cited by applicant]
Fry et al. (2010) Secreted and membrane-bound isoforms of protease ADAM9 have opposing effects on breast cancer cell migration. Cancer Research 70(20):8187-8198. [cited by applicant]
Guaiquil et al. (2009) Molecular and Cellular Biology 29(10):2694-2703. [cited by applicant]
Hartmann et al. (2002) The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for a-secretase activity in fibroblasts. Human Molecular Genetics (11):2615-24. [cited by applicant]
Hwang et al., “Furin is an endogenous regulator of alpha-secretase associated APP processing”, Biochemical and Biophysical Research Communication, 349:654-659 (2006). [cited by applicant]
International Search Report corresponding to International Patent Application No. PCT/US2018/053938 dated Feb. 5, 2019. [cited by applicant]
International Search Report corresponding to International Patent Application No. PCT/US2019/016015 dated Jun. 13, 2019. [cited by applicant]
Jefferson et al. (2013) The substrate degradome of meprin metalloproteases reveals an unexpected proteolytic link between meprin band ADAM10. Cellular and Molecular Life Sciences 70(2):309-333. [cited by applicant]
Lammich et al. (1999) Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proceedings of the National Academy of Sciences of the United States o… [cited by applicant]
Lemieux et al. (2007) The low affinity IgE receptor (CD23) is cleaved by the metalloproteinase ADAM10. The Journal of Biological Chemistry 282(20):14836-44. [cited by applicant]
Li et al. (2007) Metalloproteases regulate T-cell proliferation and effector function via LAG-3. The EMBO Journal 26(2):494-504. [cited by applicant]
Mathews et al. (2011) A potential new target for asthma therapy: a disintegrin and metalloprotease 10 (ADAM10) involvement in murine experimental asthma. Allergy 66(9):1193-200. [cited by applicant]
Mauch et al. (2010) Accelerated wound repair in ADAM-9 knockout animals. The Journal of Investigative Dermatology 130:2120-2130. [cited by applicant]
Moss et al. (2011) ADAM9 inhibition increases membrane activity of ADAM10 and controls a-secretase processing of amyloid precursor protein. Journal of Biological Chemistry 286(47):40443-40451. [cited by applicant]
Polverino et al. (2014) ADAM9 is upregulated in human COPD lungs and in human and murine lung in response to cigarette smoke European Respiratory Journal, 44(58):4856. [cited by applicant]
Roychaudhuri et al. (2014) ADAM9 is a Novel Product of Polymorphonuclear Neutrophils: Regulation of Expression and Contributions to Extracellular Matrix Protein Degradation during Acute Lung Injury, Journal of Immunolog… [cited by applicant]
Sahin et al. (2004) Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. The Journal of Cell Biology 164(5):769-79. [cited by applicant]
Schelter et al. (2010) A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor. The Journal of Biological Chemistry 285(34):26335-40. [cited by applicant]
Vazeille et al. (2011) Role of meprins to protect ileal mucosa of Crohn's disease patients from colonization by adherent-invasive [cited by applicant]
Waldhauer et al. (2008) Tumor-Associated MICA is shed by ADAM proteases. Cancer Research (68):6368-76. [cited by applicant]
Witters et al. (2008) Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neutyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Research 68(17):7083-9. [cited by applicant]
Wong et al. (2015) The Functional Maturation of a Disintegrin and Metalloproteinase (ADAM) 9, 10, and 17 Requires Processing at a Newly Identified Proprotein Convertase (PC) Cleavage Site. The Journal of Biological Chem… [cited by applicant]
Wong et al. (2016) Harnessing the natural inhibitory domain to control TNFalpha Converting Enzyme (TACE) activity in vivo. Scientific Reports 6:35598. [cited by applicant]
Zhou et al. (2006) Targeting ADAM-mediated ligand cleavage to inhibit HERS and EGFR pathways in non-small cell lung cancer. Cancer Cell 10(1):39-50. [cited by applicant]
Wetzel et al., The metalloproteinase ADAM10: a useful therapeutic target?, Biochim. Biophys. Acta. Mol. Cell Res., 1864: 2071-2081, (2017). [cited by applicant]
Wong et al., The functional maturation of a disintegrin and metalloproteinase (ADAM) 9, 10, and 17 requires processing at a newly identified proprotein convertase (PC) cleavage site, J. Biol. Chem., 290(19): 12135-12146… [cited by applicant]